Industry report · Biotech
The State of Biotech Business Development, 2026
Where new biotech business comes from right now: who buys, who signs, what makes them take the call and what a qualified first meeting looks like. Then a 5-tool kit to put it to work at your company this month.
- 6account types worth calling first
- 4people who sign or shape the decision
- 5events that open the door
- 5working tools in the kit at the back
What this guide covers, counted from our biotech talk track and industry page.
Executive summary Read this if nothing else
4 things to know about biotech business development
Call first
Venture-backed discovery-stage biotechs
Small teams building out labs after a funding round, choosing instruments, assay platforms and outsourced partners for the first time.
Who signs
Head of R&D or principal scientist
Open with this: Ask what is slowing down the current program, such as throughput, data quality or assay development time.
Best reason to call
A new funding round
Fresh capital is spent on headcount, lab buildout and outsourced work. The weeks after an announcement are when tool and service choices get made.
Why deals stall
Scientists ignore generic sales outreach
Your SDR learns your technology and leads with the experiment or process problem it solves, so the conversation sounds credible from the first call.
Sources: Abstrakt biotech talk track and industry page.
Chapter 01 The market
Where new biotech business comes from
If you sell instruments, reagents, software, bioprocess equipment or outsourced R&D to biotech companies, the person who decides is usually a scientist with a specific experiment or process problem, and the person who pays is someone else. We book meetings with the R&D and process development leaders who own those problems, timed to the funding and program milestones that open budget.
Referrals and inbound rarely fill a biotech calendar on their own. The companies that grow pick the accounts that fit, reach the person who signs, and call when something has changed at the account. That is the order of this guide, and the toolkit at the back turns each chapter into work you can start on Monday.
Chapter 02 The buyer
Who to call, and who signs
The right account, then the right person inside it. Here is where biotech business comes from, and who decides.
The accounts worth calling first
- Venture-backed discovery-stage biotechsSmall teams building out labs after a funding round, choosing instruments, assay platforms and outsourced partners for the first time.
- Clinical-stage biotechs moving toward manufacturingPrograms heading into later trials need process development, scale-up, analytics and a CDMO, and the decisions get made by a few people.
- Cell and gene therapy developersSpecialized manufacturing, vector production, analytics and cold chain needs that standard suppliers often do not cover well.
- CROs and CDMOs serving biotechService providers buy equipment, software and consumables at volume and add capacity as they win new programs.
- Industrial and synthetic biology companiesStrain engineering, fermentation and scale-up work that needs bioreactors, screening tools and process analytics.
- University spinouts and incubator tenantsEarly companies in shared lab space with grant or seed funding, often choosing their first core platforms.
The people who sign
Head of R&D or principal scientist
Signs forWhich platforms, assays and tools the lab adopts and the technical evaluation behind them.
Open withAsk what is slowing down the current program, such as throughput, data quality or assay development time.
Process development or bioprocess lead
Signs forScale-up, upstream and downstream methods, and the equipment and partners used to get there.
Open withAsk where they are in scale-up and what they plan to bring in-house versus send to a CDMO.
CSO, CTO or founder
Signs forBudget, partnerships and the final call at smaller companies.
Open withLead with the program milestone they are trying to hit and what stands in the way, not with features.
Lab manager or operations lead
Signs forPurchasing logistics, vendor setup, installation and lab space.
Open withUse them to learn what equipment is coming and who is running the evaluation, then reach the scientist who decides.
Chapter 03 The timing
What opens the door
Most biotech buyers are not shopping on the day you call. These are the changes that make them start.
- A new funding roundFresh capital is spent on headcount, lab buildout and outsourced work. The weeks after an announcement are when tool and service choices get made.
- A program moving to the next stageGoing from discovery to IND-enabling work or from early to late trials changes what the company needs to buy and who it partners with.
- New lab space or a moveBuildouts mean new instruments, informatics and services chosen in a short window.
- Key hires in R&D or process developmentA new head of a function often brings preferred tools and reviews existing vendors.
- A partner or CDMO falling shortMissed timelines or quality issues at an outsourcing partner push teams to look for a second source.
Chapter 04 The friction
Why biotech pipelines stall
Where biotech pipelines lose momentum, and what changes when they are fixed.
The problemScientists ignore generic sales outreach
What changesYour SDR learns your technology and leads with the experiment or process problem it solves, so the conversation sounds credible from the first call.
The problemThe user and the buyer are different people
What changesWe reach the scientist who will use it and the leader who funds it, and track both in the same account notes.
The problemEvaluations take a long time
What changesFollow-up stays steady through demos, data reviews and pilot runs, so deals do not stall between steps.
The problemHard to know who just got funded
What changesThe list is built around funding events, program stage and hiring, so outreach reaches companies when budget is opening.
Chapter 05 The meeting
What a qualified biotech meeting looks like
Every meeting we book for a biotech client clears three checks before it reaches the calendar: the right company, the right contact and the right timing.
- Right company. An account that fits the work you want, such as venture-backed discovery-stage biotechs.
- Right contact. Someone who signs or shapes the decision, such as the head of R&D or principal scientist.
- Right timing. A stated need or a reason to talk now, such as A new funding round.
Every meeting is then graded on our 25-point 5 Star Scorecard before it reaches a client. Use the same test on your own calendar: if you could not answer each line above before the meeting, it was not qualified yet. More on what counts as a qualified appointment.
Part two Apply this
The Biotech toolkit
5 working tools built from the chapters above. Tick the boxes as you go (they stay ticked in this browser), copy the scripts into your CRM, or save the whole guide as a PDF and print this part as a worksheet.
- 01Account scorecardScore an account before anyone dials it.
- 02Discovery question bankThe questions that qualify a meeting.
- 03Trigger watchlistThe changes that make a buyer take the call.
- 04Follow-up cadenceWhat to send after the call, and what to skip.
- 0530-day action planFour weeks of steps you can start Monday.
Tool 01
Account scorecard
Before an account goes on the call list, check every line that fits. Call the accounts with the most ticks first, and leave the ones with none for later.
Tool 02
Discovery question bank
Ask fewer, better questions. Pick three or four for the call and save the rest for the meeting. Each one comes with the reason it earns its place.
Opening with each buyer
The first question for each person who signs or shapes the decision.
- Ask what is slowing down the current program, such as throughput, data quality or assay development time.Head of R&D or principal scientist
- Ask where they are in scale-up and what they plan to bring in-house versus send to a CDMO.Process development or bioprocess lead
- Lead with the program milestone they are trying to hit and what stands in the way, not with features.CSO, CTO or founder
- Use them to learn what equipment is coming and who is running the evaluation, then reach the scientist who decides.Lab manager or operations lead
Finding the timing
One question per trigger on the watchlist. A yes is your reason to meet now.
- A new funding round: is this happening at your company, or coming up this year?
- A program moving to the next stage: is this happening at your company, or coming up this year?
- New lab space or a move: is this happening at your company, or coming up this year?
- Key hires in R&D or process development: is this happening at your company, or coming up this year?
- A partner or CDMO falling short: is this happening at your company, or coming up this year?
Any first meeting
Plain practice that works in every industry.
- How are you handling this today, and what would you change about it?The gap between today and what they want is the whole reason to meet.
- What happens if nothing changes this year?Tells you whether there is a cost to waiting, or only curiosity.
- Who else would need to agree before anything moves?Names the people who can stall the deal, while you can still invite them.
- When does the current contract or budget come up for review?Gives you the date to plan around, even when the answer today is no.
- What would make a first meeting worth your time?Lets the buyer set the agenda, which is the agenda they will show up for.
Tool 03
Trigger watchlist
Each of these changes gives a buyer a reason to take the call this month instead of next year. Tick the ones you will track, and set a news alert or CRM field for each so you hear about it first.
Tool 04
Follow-up cadence
Most deals are won or lost after the first meeting. Use these stages as your template: every touch carries a reason, and none of them is "just checking in".
After the first call
Send a short recap in the buyer's own words: the problem they named, who else is involved and the next step you agreed. Write it so they can forward it to the process development or bioprocess lead without editing.
Skip: A brochure attachment that never mentions what they told you.
Before the meeting
Confirm the time and the attendees the day before. Ask whether the process development or bioprocess lead should join the head of R&D or principal scientist. Bring one example that matches their kind of account.
Skip: Showing up with a generic deck and no questions written down.
After the meeting
Send what you promised, when you promised it, with the next step and a date on it. If a proposal is next, confirm who reads it and when they decide.
Skip: Ending on "let me know if you have questions", which leaves the next move to them.
When the answer is "not now"
Ask when the current contract, budget or plan comes up for review. Put that date in your calendar and call before it, not after.
Skip: Checking in with nothing new to say. Every touch should carry a reason.
When a trigger fires
Watch for a new funding round, a program moving to the next stage and new lab space or a move. Any one of them is a reason to call back with something specific to that change.
Skip: Waiting for the buyer to remember you when the change happens.
Tool 05
30-day action plan
4 weeks, 16 steps, nothing you need to buy. Tick each one off as you finish it; your progress stays in this browser.
Week 1Pick the accounts
Week 2Build the talk track
Week 3Make the calls
Week 4Follow up and measure
Appendix If you want it done for you
How a biotech program runs
Build the list
Biotechs, service providers and research groups that fit your product, sorted by modality, program stage, funding and location, with R&D and process contacts named.
Run the outreach
A U.S.-based SDR team works phone, email and LinkedIn under your company name, using accurate technical messaging that stays within your approved claims.
Book qualified meetings
Every meeting is with the right company, the right contact and a timing reason such as a funding round, a stage change or a new lab.
Nurture the rest
Companies not ready to evaluate stay in a follow-up cadence until the next milestone opens budget.
Sources and notes
- Abstrakt biotech talk track, target accounts, decision-makers, triggers and qualification standards, as published on our Biotech page.
- The toolkit's general advice (scorecard, core questions, follow-up stages and the 30-day plan) is sales practice, not data.
